Spyre Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Spyre Therapeutics (SYRE).

Price Target Range — 11 Quarters

Analyst Consensus — 15 Analysts

1S.Buy

14Buy

Consensus RatingBuy# Analysts15Avg. Consensus PT$99Upside to Avg. PT-3.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 5, 2026	Wells Fargo	Yanan Zhu	PT Raise	Overweight	$90→$115
Aug 5, 2026	Guggenheim	Yatin Suneja	PT Raise	Buy	$115→$130
Aug 5, 2026	Wedbush	David Nierengarten	PT Raise	Outperform	$100→$130
Jul 28, 2026	Wolfe Research	Andy Chen	Downgrade	Outperform→Peer Perform	—
Jul 13, 2026	Mizuho	Joseph Catanzaro	PT Raise	Outperform	$84→$120
Jun 23, 2026	Deutsche Bank	David Hoang	PT Raise	Buy	$115→$135
Jun 15, 2026	BTIG	Julian Harrison	PT Raise	Buy	$98→$112
Jun 4, 2026	Deutsche Bank	David Hoang	PT Raise	Buy	$102→$115
May 6, 2026	Citigroup	Samantha Semenkow	PT Raise	Buy	$64→$97
May 6, 2026	Stifel	Alex Thompson	PT Raise	Buy	$92→$107
Apr 17, 2026	Jones Trading	Debanjana Chatterjee	PT Raise	Buy	$64→$95
Apr 14, 2026	Wells Fargo	Yanan Zhu	PT Raise	Overweight	$50→$90
Apr 14, 2026	Wedbush	David Nierengarten	PT Raise	Outperform	$65→$80
Apr 14, 2026	Baird	Colleen Kusy	PT Raise	Outperform	$65→$90
Apr 14, 2026	Raymond James	Martin Auster	Initiate	Strong Buy	$80
Apr 14, 2026	Deutsche Bank	David Hoang	PT Raise	Buy	$55→$88
Apr 13, 2026	Leerink Partners	Thomas Smith	PT Raise	Outperform	$49→$106
Apr 13, 2026	Jefferies	Akash Tewari	PT Raise	Buy	$47→$85
Apr 13, 2026	BTIG	Julian Harrison	PT Raise	Buy	$70→$98
Mar 31, 2026	BTIG	Julian Harrison	Maintained	Buy	$70

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Wells Fargo Maintains Overweight on Spyre Therapeutics, Raises Price Target to $115

Wells Fargo analyst Yanan Zhu maintains Spyre Therapeutics (NASDAQ:SYRE) with a Overweight and raises the price target from $90 to $115.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Spyre Therapeutics, Raises Price Target to $130

Guggenheim analyst Yatin Suneja maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and raises the price target from $115 to $130.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Spyre Therapeutics, Raises Price Target to $130

Wedbush analyst David Nierengarten maintains Spyre Therapeutics (NASDAQ:SYRE) with a Outperform and raises the price target from $100 to $130.

Benzinga Newsdesk

PRO
Wolfe Research Downgrades Spyre Therapeutics to Peer Perform

Wolfe Research analyst Andy Chen downgrades Spyre Therapeutics (NASDAQ:SYRE) from Outperform to Peer Perform.

Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Spyre Therapeutics, Raises Price Target to $120

Mizuho analyst Joseph Catanzaro maintains Spyre Therapeutics (NASDAQ:SYRE) with a Outperform and raises the price target from $84 to $120.

Benzinga Newsdesk

PRO
Deutsche Bank Maintains Buy on Spyre Therapeutics, Raises Price Target to $135

Deutsche Bank analyst David Hoang maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and raises the price target from $115 to $135.

Benzinga Newsdesk

Spyre Therapeutics Inc

Spyre Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Wells Fargo Maintains Overweight on Spyre Therapeutics, Raises Price Target to $115

PRO
Guggenheim Maintains Buy on Spyre Therapeutics, Raises Price Target to $130

PRO
Wedbush Maintains Outperform on Spyre Therapeutics, Raises Price Target to $130

PRO
Wolfe Research Downgrades Spyre Therapeutics to Peer Perform

PRO
Mizuho Maintains Outperform on Spyre Therapeutics, Raises Price Target to $120

PRO
Deutsche Bank Maintains Buy on Spyre Therapeutics, Raises Price Target to $135

People Also Watch

People Also Watch

People Also Watch

People Also Watch

Benzinga

Benzinga

Spyre Therapeutics Inc

Spyre Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROWells Fargo Maintains Overweight on Spyre Therapeutics, Raises Price Target to $115

PROGuggenheim Maintains Buy on Spyre Therapeutics, Raises Price Target to $130

PROWedbush Maintains Outperform on Spyre Therapeutics, Raises Price Target to $130

PROWolfe Research Downgrades Spyre Therapeutics to Peer Perform

PROMizuho Maintains Outperform on Spyre Therapeutics, Raises Price Target to $120

PRODeutsche Bank Maintains Buy on Spyre Therapeutics, Raises Price Target to $135

People Also Watch

People Also Watch

People Also Watch

People Also Watch

PRO
Wells Fargo Maintains Overweight on Spyre Therapeutics, Raises Price Target to $115

PRO
Guggenheim Maintains Buy on Spyre Therapeutics, Raises Price Target to $130

PRO
Wedbush Maintains Outperform on Spyre Therapeutics, Raises Price Target to $130

PRO
Wolfe Research Downgrades Spyre Therapeutics to Peer Perform

PRO
Mizuho Maintains Outperform on Spyre Therapeutics, Raises Price Target to $120

PRO
Deutsche Bank Maintains Buy on Spyre Therapeutics, Raises Price Target to $135